Drug intelligence / Profile preview

consolidation + I HAM

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous

Overview

Consolidation + I HAM is not a single pharmaceutical drug but rather refers to a chemotherapy regimen used in the treatment of acute myeloid leukemia (AML). "Consolidation" refers to post-remission therapy aimed at eliminating residual disease after initial induction chemotherapy. "I HAM" stands for **Intermediate-dose Ara-C (cytarabine) and Mitoxantrone**, which are administered together as part of this regimen. The combination is designed to further reduce leukemic cell burden and improve long-term outcomes in AML patients following remission induction.

Targets

DNA polymerase familyTOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on consolidation + I HAM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on consolidation + I HAM.

Explore the full profile